CADL
Candel Therapeutics, Inc.·Healthcare
4.83
0.625%(+0.03)
Market ClosedLast Updated: — ET
52W L: $4.3452W H: $7.25
CADL NEWS
globenewswire.com
Apr 2
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on March 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to five new employees, stock options to purchase an aggregate of 70,000 shares of the Company's common stock, with a per share exercise price of $4.90.
defenseworld.net
Mar 21
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives $18.00 Average Target Price from Brokerages
Shares of Candel Therapeutics, Inc. (NASDAQ: CADL - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy
proactiveinvestors.com
Mar 17
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing phase 2a trial of aglatimagene besadenovec (CAN-2409) in patients with advanced non-small cell lung cancer (NSCLC) who had previously shown an inadequate response to immune checkpoint inhibitors (ICIs). The additional 12 months of follow-up data indicate that 50% of the 46 patients in the per-protocol population remained alive at 24 months after treatment.
proactiveinvestors.com
Mar 17
Goldman Sachs says the era of low hiring and low firing is here to stay, and that may be good news
The bank's economists argue that what looks like a fragile jobs market is actually a sign that workers and employers have gotten much better at finding each...
globenewswire.com
Mar 17
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
NEEDHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced an additional 12 months of extended follow-up from its study of aglatimagene plus valacyclovir in combination with continued ICI therapy in patients with advanced NSCLC who had an inadequate response to prior ICI treatment. Among the 46 patients who received two administrations of aglatimagene (per-protocol population), 23 patients (50%) remained alive at 24 months. Additionally, 16 patients (35%) survived beyond 30 months, 12 patients (26%) survived beyond 36 months, 11 patients (24%) survived beyond 40 months, and 6 patients (13%) exceeded 50 months of survival. These outcomes represent an improvement from the prior data cut, in which 39% of the patients in the per-protocol population were alive at 24 months, with 10 patients surviving beyond 30 months, 6 patients each beyond 36 and 40 months, and 2 patients beyond 50 months. The extended follow-up further highlights the durability of anti-tumor immunity observed with aglatimagene-based therapy, and the persistence of a long-term survival tail in this difficult-to-treat population.
proactiveinvestors.com
Mar 17
Dell shrinks workforce by 11,000 in fiscal 2026 amid ongoing restructuring
Dell Technologies Inc (NASDAQ:DELL) reduced its workforce by roughly 11,000 employees in fiscal 2026, bringing total headcount to about 97,000 as of January...
